<DOC>
	<DOCNO>NCT01786096</DOCNO>
	<brief_summary>This phase 1 , open-label , dose-escalation , multicenter study evaluate safety tolerability SGN-CD19A adult pediatric patient relapse refractory B-lineage acute lymphoblastic leukemia ( B-ALL ) , Burkitt lymphoma leukemia , B-lineage lymphoblastic lymphoma ( B-LBL ) .</brief_summary>
	<brief_title>A Safety Study SGN-CD19A Leukemia Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Adult patient must relapse refractory least 1 prior multiagent systemic therapy . Pediatric patient must relapse refractory least 2 prior multiagent systemic therapy . Patients acute lymphoblastic leukemia Philadelphia chromosomepositive must fail second generation tyrosine kinase inhibitor . Eastern Cooperative Oncology Group status 2 low Pathologically confirm diagnosis Blineage acute lymphoblastic leukemia , Burkitt leukemia lymphoma , Blineage lymphoblastic lymphoma Measurable disease Allogeneic stem cell transplant within 60 day , active acute chronic graftversushost disease ( GvHD ) , receive immunosuppressive therapy treatment GvHD</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Burkitt Lymphoma</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>B-Lineage Acute Lymphoblastic Leukemia</keyword>
	<keyword>B-Lineage Lymphoblastic Lymphoma</keyword>
	<keyword>Burkitt Leukemia</keyword>
	<keyword>Monomethylauristatin F</keyword>
	<keyword>Antigens , CD19</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>